ZBTB2 links p53 deficiency to HIF‐1‐mediated hypoxia signaling to promote cancer aggressiveness
Authors:
- Sho KoyasuSKSho Koyasu
- Shoichiro HoritaSHShoichiro Horita
- Keisuke SaitoKSKeisuke Saito
- Minoru KobayashiMKMinoru Kobayashi
- Hiroshi IshikitaHIHiroshi Ishikita
- Christalle Ct ChowCCChristalle Ct Chow
- Gouki KambeGKGouki Kambe
- Toshi MenjuTMToshi Menju
- Yasushi OkochiYOYasushi Okochi
- Yoshiaki TabuchiYTYoshiaki Tabuchi
- 7 November 2022
- journal article
- research article
- Published by Springer Nature in EMBO Reports
- Vol. 24 (1) , e54042
Abstract
Aberrant activation of the hypoxia-inducible transcription factor HIF-1 and dysfunction of the tumor suppressor p53 have been reported to induce malignant phenotypes and therapy resistance of cancers. However, their mechanistic and functional relationship remains largely unknown. Here, we reveal a mechanism by which p53 deficiency triggers the activation of HIF-1-dependent hypoxia signaling and identify zinc finger and BTB domain-containing protein 2 (ZBTB2) as an important mediator. ZBTB2 forms homodimers via its N-terminus region and increases the transactivation activity of HIF-1 only when functional p53 is absent. The ZBTB2 homodimer facilitates invasion, distant metastasis, and growth of p53-deficient, but not p53-proficient, cancers. The intratumoral expression levels of ZBTB2 are associated with poor prognosis in lung cancer patients. ZBTB2 N-terminus-mimetic polypeptides competitively inhibit ZBTB2 homodimerization and significantly suppress the ZBTB2-HIF-1 axis, leading to antitumor effects. Our data reveal an important link between aberrant activation of hypoxia signaling and loss of a tumor suppressor and provide a rationale for targeting a key mediator, ZBTB2, to suppress cancer aggressiveness.Keywords
Funding Information
- Foundation for Promotion of Cancer Research
- Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care
- Japan Agency for Medical Research and Development (17933766)
- Japan Agency for Medical Research and Development (A101)
- Japan Agency for Medical Research and Development (21gm1110010s0203)
- Japan Agency for Medical Research and Development (22ama221417h0001)
- Kobayashi Foundation for Cancer Research
- Japan Society for the Promotion of Science (JPJSCCA20200009)
- Japan Society for the Promotion of Science (18KK0241)
- Japan Society for the Promotion of Science (19K22595)
- Japan Society for the Promotion of Science (20H03621)
- Japan Society for the Promotion of Science (20H05033)
- Japan Society for the Promotion of Science (21KK0144)
- Japan Society for the Promotion of Science (21K19445)
- Japan Society for the Promotion of Science (21K07727)
- Japan Society for the Promotion of Science (16H06891)
- Japan Society for the Promotion of Science (17J07699)
- Japan Society for the Promotion of Science (19K17164)
- Princess Takamatsu Cancer Research Fund
- Takeda Science Foundation
- Uehara Memorial Foundation
- Yasuda Memorial Medical Foundation
This publication has 39 references indexed in Scilit:
- Identification of Candidate Oncogenes in Human Colorectal Cancers With Microsatellite InstabilityGastroenterology, 2013
- The CEACAM1 tumor suppressor is an ATM and p53-regulated gene required for the induction of cellular senescence by DNA damageOncogenesis, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeuticsOncogene, 2009
- ZBTB2, a Novel Master Regulator of the p53 PathwayJournal of Biological Chemistry, 2009
- The SWISS-MODEL Repository and associated resourcesNucleic Acids Research, 2008
- Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylasesBiochemical and Biophysical Research Communications, 2005
- Scalable molecular dynamics with NAMDJournal of Computational Chemistry, 2005
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- Chromosome 17 Deletions and p53 Gene Mutations in Colorectal CarcinomasScience, 1989